Colorectal neoplasia pathways: State of the art

Gastrointestinal Endoscopy Clinics of North America

Volumn 25, Issue 2, 2015, Pages 169-182

  IJspeert, Joep Evert Godfried ^a   Medema, Jan Paul ^a   Dekker, Evelien ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Chromosomal instability; Colonoscopy; Colorectal cancer; Colorectal polyps; Microsatellite instability; Serrated neoplasia pathway

Indexed keywords

CANCER GROWTH; CHROMOSOMAL INSTABILITY; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; COLORECTAL POLYP; HISTOPATHOLOGY; HUMAN; MICROSATELLITE INSTABILITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ADENOMA; CARCINOGENESIS; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; PATHOLOGY; PRECANCEROUS CONDITIONS; PROCEDURES; RISK FACTOR;

ADENOMA; CARCINOGENESIS; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; HUMANS; MICROSATELLITE INSTABILITY; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 84926157585     PISSN: 10525157     EISSN: 15581950     Source Type: Journal    
DOI: 10.1016/j.giec.2014.11.004     Document Type: Review

References (78)

1. Sideris M., Papagrigoriadis S. Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer. Anticancer Res 2014, 34(5):2061-2068.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30. 10.3322/caac.21166.
3. Colussi D., Brandi G., Bazzoli F., et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013, 14:16365-16385. 10.3390/ijms140816365.
4. Jackman R., Mayo C. The adenoma-carcinoma sequence in cancer of the colon. Surg Gynecol Obstet 1951, 93(3):327-330.
5. Fearon E.F., Vogelstein B. Agenetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
6. Fearon E.R. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011, 6:479-507. 10.1146/annurev-pathol-011110-130235.
7. Pino M.S., Chung D.C. The chromosomal instability pathway in colon cancer. Gastroenterology 2010, 138(6):2059-2072. 10.1053/j.gastro.2009.12.065.
8. Leggett B., Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010, 138:2088-2100. 10.1053/j.gastro.2009.12.066.
9. Boland C.R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010, 138. 10.1053/j.gastro.2009.12.064.
10. Jass J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50(1):113-130. 10.1111/j.1365-2559.2006.02549.x.
11. Snover D.C. Update on the serrated pathway to colorectal carcinoma. Hum Pathol 2011, 42(1):1-10. 10.1016/j.humpath.2010.06.002.
12. Toyota M., Ahuja N., Ohe-Toyota M., et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999, 96:8681-8686. 10.1073/pnas.96.15.8681.
13. Torlakovic E., Skovlund E., Snover D.C., et al. Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol 2003, 27(1):65-81. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/12502929.
14. Hofstad B., Vatn M.H., Andersen S.N., et al. Growth of colorectal polyps: redetection and evaluation of unresected polyps for a period of three years. Gut 1996, 39(3):449-456.
15. Pickhardt P.J., Kim D.H., Pooler B.D., et al. Assessment of volumetric growth rates of small colorectal polyps with CT colonography: a longitudinal study of natural history. Lancet Oncol 2013, 14:711-720. 10.1016/S1470-2045(13)70216-X.
16. Bosman F.T., Carneiro F., Hruban R. World Health Organization classification of tumours of the digestive system 2010, 160-165. IARC Press, Lyon (France).
17. Muto T., Bussey H.J., Morson B. The evolution of cancer of the colon and rectum. Cancer 1975, 6(36):2251-2270.
18. Brenner H., Hoffmeister M., Stegmaier C., et al. Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies. Gut 2007, 56:1585-1589. 10.1136/gut.2007.122739.
19. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature 1998, 396:643-649. 10.1038/25292.
20. Decordier I., Cundari E., Kirsch-Volders M. Mitotic checkpoints and the maintenance of the chromosome karyotype. Mutat Res 2008, 651:3-13. 10.1016/j.mrgentox.2007.10.020.
21. Powell S.M., Zilz N., Beazer-Barclay Y., et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992, 359:235-237. 10.1038/359235a0.
22. Bodmer W., Bailey C., Bodmer J., et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987, 328(6131):614-616.
23. Sierra J., Yoshida T., Joazeiro C.A., et al. The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev 2006, 20:586-600. 10.1101/gad.1385806.
24. Morin P.J., Sparks A.B., Korinek V., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790. 10.1126/science.275.5307.1787.
25. Church D., Midgley R., Kerr D. Biomarkers in early-stage colorectal cancer: ready for prime time?. Dig Dis 2012, 30(Suppl 2):27-33. 10.1159/000341890.
26. Pruitt K., Der C.J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 2001, 171:1-10. 10.1016/S0304-3835(01)00528-6.
27. Baker S.J., Preisinger A.C., Jessup J.M., et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990, 50:7717-7722.
28. Bálint E.E., Vousden K.H. Activation and activities of the p53 tumour suppressor protein. Br J Cancer 2001, 85:1813-1823. 10.1054/bjoc.2001.2128.
29. Leslie A., Carey F.A., Pratt N.R., et al. The colorectal adenoma-carcinoma sequence. Br J Surg 2002, 89(7):845-860. 10.1046/j.1365-2168.2002.02120.x.
30. Vogelstein B., Fearon E.R., Hamilton S.R., et al. Genetic alterations during colorectal-tumor development. NEngl J Med 1988, 319:525-532. 10.1097/00043764-198910000-00001.
31. Lanza G., Matteuzzi M., Gafá R., et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998, 79:390-395. pii:10.1002/(SICI)1097-0215(19980821)79:4<390::AID-IJC14>3.0.CO;2-9.
32. Lynch H.T., Smyrk T., Lynch J.F. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome). Int J Cancer 1996, 69:38-43. pii:10.1002/(SICI)1097-0215(19960220)69:1<38::AID-IJC9>3.0.CO;2-X.
33. Edelstein D.L., Axilbund J., Baxter M., et al. Rapid development of colorectal neoplasia in patients with lynch syndrome. Clin Gastroenterol Hepatol 2011, 9:340-343. 10.1016/j.cgh.2010.10.033.
34. Lee J.K., Chan A.T. Molecular prognostic and predictive markers in colorectal cancer: current status. Curr Colorectal Cancer Rep 2011, 7:136-144. 10.1007/s11888-011-0091-4.
35. Perez-Cabornero L., Sanz M.I., Sampedro E.V., et al. Frequency of rearrangements in lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5' part of MSH2. Cancer Prev Res (Phila) 2011, 4:1556-1562. 10.1158/1940-6207.CAPR-11-0080.
36. North P., Thomas D.C., Umar A., et al. Microsatellite instability and mismatch repair defects in cancer cells. Mutat Res 1996, 350:201-205.
37. Miyaki M., Iijima T., Kimura J., et al. Frequent mutation of beta-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. Cancer Res 1999, 59:4506-4509.
38. Markowitz S., Wang J., Myeroff L., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338. 10.1126/science.7761852.
39. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator ofthe human bax gene. Cell 1995, 80:293-299. 10.1016/0092-8674(95)90412-3.
40. Yagi O.K., Akiyama Y., Nomizu T., et al. Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas. Gastroenterology 1998, 114:268-274. 10.1016/S0016-5085(98)70477-9.
41. Abdeljawad K., Vemulapalli K.C., Kahi C.J., et al. Sessile serrated polyp prevalence determined by a colonoscopist with a high lesion detection rate and an experienced pathologist. Gastrointest Endosc 2014, 10.1016/j.gie.2014.04.064.
42. Hazewinkel Y., de Wijkerslooth T.R., Stoop E.M., et al. Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy. Endoscopy 2014, 46(3):219-224. 10.1055/s-0033-1358800.
43. O'Brien M.J., Yang S., Mack C., et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol 2006, 30:1491-1501. 10.1097/01.pas.0000213313.36306.85.
44. Burnett-Hartman A.N., Newcomb P.A., Potter J.D., et al. Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res 2013, 73:2863-2872. 10.1158/0008-5472.CAN-12-3462.
45. Fernando W.C., Miranda M.S., Worthley D.L., et al. The CIMP phenotype in BRAF mutant serrated polyps from a prospective colonoscopy patient cohort. Gastroenterol Res Pract 2014, 2014:374926. 10.1155/2014/374926.
46. Rex D.K., Ahnen D.J., Baron J.A., et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012, 107:1315-1329. [quiz: 1314, 1330]. 10.1038/ajg.2012.161.
47. Hoff G. New polyps, old tricks: controversy about removing benign bowel lesions. Br Med J 2013, 347:f5843. 10.1136/bmj.f5843.
48. Lu F.I., van Niekerk D.W., Owen D., et al. Longitudinal outcome study of sessile serrated adenomas of the colorectum: an increased risk for subsequent right-sided colorectal carcinoma. Am J Surg Pathol 2010, 34:927-934. 10.1097/PAS.0b013e3181e4f256.
49. De Sousa E Melo F., Wang X., Jansen M., et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013, 19(5):614-618. 10.1038/nm.3174.
50. Iino H., Jass J.R., Simms L.A., et al. DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer?. JClin Pathol 1999, 52:5-9. 10.1136/jcp.52.1.5.
51. Boparai K.S., Dekker E., Polak M.M., et al. Aserrated colorectal cancer pathway predominates over the classic WNT pathway in patients with hyperplastic polyposis syndrome. Am J Pathol 2011, 178(6):2700-2707. 10.1016/j.ajpath.2011.02.023.
52. Edelstein D.L., Axilbund J.E., Griffin C.A., et al. Serrated polyposis: rapid and relentless development of colorectal neoplasia. Gut 2013, 62(3):404-408. 10.1136/gutjnl-2011-300514.
53. Lash R.H., Genta R.M., Schuler C.M. Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. JClin Pathol 2010, 63(8):681-686. 10.1136/jcp.2010.075507.
54. Chan A.O., Issa J.P., Morris J.S., et al. Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol 2002, 160:529-536. 10.1016/S0002-9440(10)64872-9.
55. Yamamoto H., Min Y., Itoh F., et al. Differential involvement of the hypermethylator phenotype in hereditary and sporadic colorectal cancers with high-frequency microsatellite instability. Genes Chromosomes Cancer 2002, 33:322-325. 10.1002/gcc.10010.
56. Kriegl L., Neumann J., Vieth M., et al. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol 2011, 24(7):1015-1022. 10.1038/modpathol.2011.43.
57. Wajapeyee N., Serra R.W., Zhu X., et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008, 132:363-374. 10.1016/j.cell.2007.12.032.
58. Kambara T., Simms L.A., Whitehall V.L., et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004, 53:1137-1144. 10.1136/gut.2003.037671.
59. Rajagopalan H., Bardelli A., Lengauer C., et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934. 10.1038/418934a.
60. Burnett-Hartman A.N., Passarelli M.N., Adams S.V., et al. Differences in epidemiologic risk factors for colorectal adenomas and serrated polyps by lesion severity and anatomical site. Am J Epidemiol 2013, 177(7):625-637. 10.1093/aje/kws282.
61. Winawer S.J., Zauber A.G., Ho M.N., et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. NEngl J Med 1993, 329:1977-1981. 10.1056/NEJM199312303292701.
62. Heldwein W., Dollhopf M., Meining A., et al. The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies. Endoscopy 2005, 37(11):1116-1122. 10.1055/s.
63. Hassan C., Pickhardt P.J., Rex D.K. Aresect and discard strategy would improve cost-effectiveness of colorectal cancer screening. Clin Gastroenterol Hepatol 2010, 8(10):865-869. 10.1016/j.cgh.2010.05.018.
64. Hassan C., Pickhardt P.J., Kim D.H., et al. Systematic review: distribution of advanced neoplasia according to polyp size at screening colonoscopy. Aliment Pharmacol Ther 2010, 31:210-217. 10.1111/j.1365-2036.2009.04160.x.
65. Winawer S.J., Zauber A.G. The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Am 2002, 12:1-9. 10.1016/S1052-5157(03)00053-9.
66. Soetikno R.M., Kaltenbach T., Rouse R.V., et al. Prevalence of nonpolypoid (flatand depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA 2008, 299:1027-1035. 10.1016/S0739-5930(08)79073-1.
67. Lambert R., Lightdale C.J. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon - Paris, France November 30 to December 1, 2002: foreword. Gastrointest Endosc 2003, 58. 10.1016/S0016-5107(03)02168-0.
68. Van Doorn S., Hazewinkel Y., East J., et al. Polyp morphology: an interobserver evaluation for the Paris classification among international experts. Am J Gastroenterol 2014, [Epub ahead of print].
69. Kudo S., Tamura S., Nakajima T., et al. Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc 1996, 44(1):8-14.
70. Su M.Y., Ho Y.P., Chen P.C., et al. Magnifying endoscopy with indigo carmine contrast for differential diagnosis of neoplastic and nonneoplastic colonic polyps. Dig Dis Sci 2004, 49:1123-1127. 10.1023/B: DDAS.0000037798.55845.f7.
71. Rosty C., Hewett D.G., Brown I.S., et al. Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management. J Gastroenterol 2013, 48(3):287-302. 10.1007/s00535-012-0720-y.
72. Bouwens M.W., van Herwaarden Y.J., Winkens B., et al. Endoscopic characterization of sessile serrated adenomas/polyps with and without dysplasia. Endoscopy 2014, 46(3):225-235. 10.1055/s-0034-1364936.
73. Tadepalli U.S., Feihel D., Miller K.M., et al. Amorphologic analysis of sessile serrated polyps observed during routine colonoscopy (with video). Gastrointest Endosc 2011, 74(6):1360-1368. 10.1016/j.gie.2011.08.008.
74. Hazewinkel Y., López-Cerón M., East J.E., et al. Endoscopic features of sessile serrated adenomas: validation by international experts using high-resolution white-light endoscopy and narrow-band imaging. Gastrointest Endosc 2013, 77(6):916-924. 10.1016/j.gie.2012.12.018.
75. Farris A.B., Misdraji J., Srivastava A., et al. Sessile serrated adenoma: challenging discrimination from other serrated colonic polyps. Am J Surg Pathol 2008, 32:30-35. 10.1097/PAS.0b013e318093e40a.
76. Hewett D.G., Kaltenbach T., Sano Y., et al. Validation of a simple classification system for endoscopic diagnosis of small colorectal polyps using narrow-band imaging. Gastroenterology 2012, 143(3):599-607.e1. 10.1053/j.gastro.2012.05.006.
77. Hayashi N., Tanaka S., Hewett D.G., et al. Endoscopic prediction of deep submucosal invasive carcinoma: validation of the narrow-band imaging international colorectal endoscopic (NICE) classification. Gastrointest Endosc 2013, 78:625-632. 10.1016/j.gie.2013.04.185.
78. Kumar S., Fioritto A., Mitani A., et al. Optical biopsy of sessile serrated adenomas: do these lesions resemble hyperplastic polyps under narrow-band imaging?. Gastrointest Endosc 2013, 78(6):902-909. 10.1016/j.gie.2013.06.004.